Medpace Holdings Key Executives
This section highlights Medpace Holdings's key executives, including their titles and compensation details.
Find Contacts at Medpace Holdings
(Showing 0 of )
Medpace Holdings Earnings
This section highlights Medpace Holdings's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Date:
July 28, 2025
Time:
After Market
Est. EPS:
$2.99
Status:
Unconfirmed
Last Earnings Results
Date:
April 21, 2025
EPS:
$3.67
Est. EPS:
$3.06
Revenue:
$558.57M
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q1 | 2025 | 2025-04-22 | N/A | N/A |
| Read Transcript | Q4 | 2024 | 2025-02-11 | N/A | N/A |
| Read Transcript | Q3 | 2024 | 2024-10-22 | N/A | N/A |
| Read Transcript | Q2 | 2024 | 2024-07-23 | N/A | N/A |
| Read Transcript | Q1 | 2024 | 2024-04-23 | N/A | N/A |
| Read Transcript | Q4 | 2023 | 2024-02-13 | N/A | N/A |
| Read Transcript | Q3 | 2023 | 2023-10-24 | N/A | N/A |
| Read Transcript | Q2 | 2023 | 2023-07-25 | N/A | N/A |
| Read Transcript | Q1 | 2023 | 2023-04-25 | N/A | N/A |
Financial Statements
Access annual & quarterly financial statements for Medpace Holdings, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $2.11B | $1.89B | $1.46B | $1.14B | $925.92M |
| Cost of Revenue | $1.45B | $1.36B | $1.03B | $814.22M | $647.20M |
| Gross Profit | $656.30M | $524.50M | $432.44M | $328.15M | $278.73M |
| Gross Profit Ratio | 31.12% | 27.81% | 29.62% | 28.73% | 30.10% |
| Research and Development Expenses | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $- | $159.85M | $130.10M | $107.22M | $91.46M |
| Selling and Marketing Expenses | $- | $1.50M | $1.30M | $1.20M | $700.00K |
| Selling General and Administrative Expenses | $180.18M | $161.35M | $131.40M | $108.42M | $92.16M |
| Other Expenses | $29.25M | $26.33M | $22.34M | $21.12M | $19.53M |
| Operating Expenses | $209.44M | $187.68M | $153.74M | $129.54M | $111.68M |
| Cost and Expenses | $1.66B | $1.55B | $1.18B | $943.76M | $758.88M |
| Interest Income | $- | $- | $2.90M | $105.00K | $307.00K |
| Interest Expense | $- | $488.00K | $2.90M | $105.00K | $307.00K |
| Depreciation and Amortization | $- | $26.33M | $40.36M | $37.41M | $33.45M |
| EBITDA | $446.87M | $363.15M | $301.04M | $219.73M | $186.57M |
| EBITDA Ratio | 21.19% | 19.26% | 20.62% | 19.23% | 20.15% |
| Operating Income | $446.87M | $336.82M | $278.70M | $198.62M | $167.04M |
| Operating Income Ratio | 21.19% | 17.86% | 19.09% | 17.39% | 18.04% |
| Total Other Income Expenses Net | $29.05M | $-1.14M | $4.16M | $3.24M | $1.49M |
| Income Before Tax | $475.92M | $335.68M | $282.86M | $201.85M | $168.53M |
| Income Before Tax Ratio | 22.57% | 17.80% | 19.37% | 17.67% | 18.20% |
| Income Tax Expense | $71.54M | $52.87M | $37.49M | $20.00M | $23.15M |
| Net Income | $404.39M | $282.81M | $245.21M | $181.39M | $144.93M |
| Net Income Ratio | 19.17% | 15.00% | 16.80% | 15.88% | 15.65% |
| EPS | $13.06 | $9.20 | $7.57 | $5.06 | $4.07 |
| EPS Diluted | $12.63 | $8.88 | $7.28 | $4.81 | $3.84 |
| Weighted Average Shares Outstanding | 30.96M | 30.72M | 32.39M | 35.86M | 35.63M |
| Weighted Average Shares Outstanding Diluted | 32.01M | 31.84M | 33.67M | 37.70M | 37.71M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | March 31, 2025 | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $558.57M | $536.59M | $533.32M | $528.10M | $511.04M | $498.40M | $492.50M | $460.87M | $434.07M | $394.10M | $383.74M | $351.21M | $330.95M | $308.55M | $295.57M | $278.29M | $259.96M | $259.68M | $230.37M | $205.00M |
| Cost of Revenue | $380.22M | $358.27M | $364.31M | $381.50M | $355.90M | $361.60M | $359.31M | $336.55M | $303.88M | $278.37M | $264.71M | $252.21M | $232.27M | $220.57M | $208.47M | $203.64M | $181.54M | $176.83M | $156.21M | $148.36M |
| Gross Profit | $178.35M | $178.32M | $169.01M | $146.60M | $155.14M | $136.81M | $133.19M | $124.32M | $130.19M | $115.73M | $119.03M | $99.00M | $98.68M | $87.98M | $87.09M | $74.65M | $78.43M | $82.85M | $74.16M | $56.64M |
| Gross Profit Ratio | 31.93% | 33.23% | 31.69% | 27.76% | 30.36% | 27.45% | 27.04% | 26.97% | 29.99% | 29.37% | 31.02% | 28.19% | 29.82% | 28.52% | 29.47% | 26.82% | 30.17% | 31.91% | 32.19% | 27.63% |
| Research and Development Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $41.01M | $- | $- | $- | $32.10M | $- | $- | $- | $26.46M | $- | $- | $- | $25.12M | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $1.50M | $- | $- | $- | $1.30M | $- | $- | $- | $1.20M | $- | $- | $- | $-2.74M | $- | $- |
| Selling General and Administrative Expenses | $57.90M | $45.43M | $49.22M | $41.45M | $44.08M | $42.51M | $41.41M | $39.40M | $38.03M | $33.40M | $35.42M | $33.22M | $29.37M | $27.66M | $28.05M | $26.97M | $25.74M | $22.38M | $22.80M | $21.86M |
| Other Expenses | $6.93M | $7.51M | $7.52M | $-133.00K | $4.59M | $3.47M | $-1.60M | $6.52M | $5.96M | $5.90M | $5.79M | $5.54M | $5.11M | $1.09M | $1.06M | $265.00K | $924.00K | $-257.00K | $584.00K | $239.00K |
| Operating Expenses | $64.83M | $52.94M | $56.73M | $41.45M | $51.07M | $49.49M | $48.28M | $45.92M | $43.98M | $39.30M | $41.21M | $38.76M | $34.47M | $33.13M | $33.38M | $32.20M | $30.83M | $27.86M | $27.74M | $26.51M |
| Cost and Expenses | $445.05M | $411.21M | $421.04M | $422.95M | $406.98M | $411.08M | $407.59M | $382.48M | $347.87M | $317.67M | $305.92M | $290.97M | $266.74M | $253.70M | $241.85M | $235.84M | $212.37M | $204.69M | $183.95M | $174.87M |
| Interest Income | $- | $- | $- | $- | $- | $1.84M | $105.00K | $1.37M | $- | $827.00K | $1.58M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $5.46M | $4.12M | $1.84M | $105.00K | $1.37M | $- | $827.00K | $1.58M | $548.00K | $54.00K | $23.00K | $41.00K | $27.00K | $14.00K | $286.00K | $16.00K | $5.00K |
| Depreciation and Amortization | $- | $- | $7.52M | $7.24M | $6.99M | $6.97M | $6.88M | $11.42M | $5.96M | $10.45M | $10.29M | $9.97M | $9.64M | $9.88M | $9.31M | $9.23M | $8.99M | $5.48M | $4.94M | $4.65M |
| EBITDA | $113.52M | $125.38M | $126.29M | $112.39M | $111.06M | $94.29M | $90.18M | $88.53M | $92.16M | $84.93M | $93.77M | $72.51M | $69.31M | $60.32M | $64.09M | $51.94M | $52.69M | $60.47M | $51.36M | $34.78M |
| EBITDA Ratio | 20.32% | 23.37% | 23.68% | 21.28% | 21.73% | 18.92% | 18.31% | 19.21% | 21.23% | 21.55% | 24.43% | 20.65% | 20.94% | 19.55% | 21.68% | 18.66% | 20.27% | 23.29% | 22.30% | 16.97% |
| Operating Income | $113.52M | $125.38M | $112.27M | $105.15M | $104.07M | $87.32M | $84.91M | $78.39M | $86.20M | $76.43M | $77.83M | $60.24M | $64.20M | $54.85M | $53.71M | $42.45M | $47.60M | $54.99M | $46.42M | $30.13M |
| Operating Income Ratio | 20.32% | 23.37% | 21.05% | 19.91% | 20.36% | 17.52% | 17.24% | 17.01% | 19.86% | 19.39% | 20.28% | 17.15% | 19.40% | 17.78% | 18.17% | 15.25% | 18.31% | 21.18% | 20.15% | 14.70% |
| Total Other Income Expenses Net | $4.65M | $8.50M | $6.50M | $5.33M | $8.71M | $3.39M | $-1.71M | $-2.65M | $-174.00K | $-2.79M | $4.07M | $1.76M | $1.12M | $1.07M | $1.02M | $238.00K | $910.00K | $-286.00K | $568.00K | $234.00K |
| Income Before Tax | $118.17M | $133.88M | $118.78M | $110.48M | $112.78M | $90.71M | $83.20M | $75.74M | $86.03M | $73.64M | $81.89M | $62.00M | $65.32M | $55.92M | $54.74M | $42.69M | $48.51M | $54.70M | $46.99M | $30.36M |
| Income Before Tax Ratio | 21.16% | 24.95% | 22.27% | 20.92% | 22.07% | 18.20% | 16.89% | 16.44% | 19.82% | 18.69% | 21.34% | 17.65% | 19.74% | 18.12% | 18.52% | 15.34% | 18.66% | 21.07% | 20.40% | 14.81% |
| Income Tax Expense | $3.58M | $16.86M | $22.35M | $22.13M | $10.19M | $12.41M | $12.65M | $14.68M | $13.14M | $4.97M | $15.87M | $12.64M | $4.01M | $5.89M | $6.16M | $2.75M | $5.20M | $3.84M | $5.53M | $6.26M |
| Net Income | $114.59M | $117.02M | $96.43M | $88.35M | $102.55M | $78.25M | $70.50M | $61.03M | $72.89M | $68.62M | $65.98M | $49.33M | $61.27M | $49.99M | $48.42M | $39.81M | $43.17M | $50.66M | $41.33M | $24.04M |
| Net Income Ratio | 20.52% | 21.81% | 18.08% | 16.73% | 20.07% | 15.70% | 14.32% | 13.24% | 16.79% | 17.41% | 17.19% | 14.05% | 18.52% | 16.20% | 16.38% | 14.30% | 16.60% | 19.51% | 17.94% | 11.73% |
| EPS | $3.77 | $3.78 | $3.11 | $2.85 | $3.32 | $2.55 | $2.30 | $2.00 | $2.35 | $2.20 | $2.13 | $1.52 | $1.75 | $1.39 | $1.35 | $1.11 | $1.21 | $1.42 | $1.16 | $0.68 |
| EPS Diluted | $3.67 | $3.67 | $3.01 | $2.75 | $3.20 | $2.46 | $2.22 | $1.93 | $2.27 | $2.11 | $2.05 | $1.46 | $1.69 | $1.32 | $1.29 | $1.06 | $1.14 | $1.34 | $1.09 | $0.64 |
| Weighted Average Shares Outstanding | 30.39M | 30.95M | 31.05M | 30.99M | 30.84M | 30.72M | 30.63M | 30.54M | 31.01M | 31.19M | 31.01M | 32.49M | 34.92M | 35.98M | 31.01M | 35.89M | 35.75M | 35.58M | 35.55M | 35.39M |
| Weighted Average Shares Outstanding Diluted | 31.20M | 32.01M | 32.09M | 32.09M | 32.00M | 31.82M | 31.76M | 31.57M | 32.16M | 32.42M | 32.25M | 33.70M | 36.36M | 37.74M | 32.25M | 37.71M | 37.75M | 37.65M | 37.76M | 37.33M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $669.44M | $245.45M | $28.27M | $461.30M | $277.77M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $669.44M | $245.45M | $28.27M | $461.30M | $277.77M |
| Net Receivables | $296.44M | $298.40M | $253.40M | $186.43M | $160.96M |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $63.35M | $49.98M | $52.29M | $86.35M | $69.85M |
| Total Current Assets | $1.03B | $593.83M | $333.96M | $690.91M | $473.65M |
| Property Plant Equipment Net | $252.26M | $265.39M | $248.92M | $222.71M | $198.83M |
| Goodwill | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M |
| Intangible Assets | $34.37M | $35.81M | $38.01M | $41.36M | $46.47M |
| Goodwill and Intangible Assets | $696.76M | $698.21M | $700.40M | $703.76M | $708.87M |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $100.36M | $74.44M | $48.08M | $25.13M | $536.00K |
| Other Non-Current Assets | $22.25M | $24.97M | $21.13M | $17.42M | $8.79M |
| Total Non-Current Assets | $1.07B | $1.06B | $1.02B | $969.02M | $917.03M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $2.10B | $1.66B | $1.35B | $1.66B | $1.39B |
| Account Payables | $32.53M | $31.87M | $33.07M | $25.68M | $26.55M |
| Short Term Debt | $- | $- | $69.27M | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $559.86M | $462.73M | $344.64M | $255.66M |
| Other Current Liabilities | $1.07B | $333.40M | $238.40M | $186.90M | $157.89M |
| Total Current Liabilities | $1.10B | $925.13M | $803.47M | $557.22M | $440.11M |
| Long Term Debt | $126.23M | $142.12M | $138.87M | $130.97M | $115.14M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $1.80M | $2.40M | $1.07M | $1.08M | $13.55M |
| Other Non-Current Liabilities | $42.73M | $28.22M | $23.77M | $17.75M | $16.09M |
| Total Non-Current Liabilities | $170.77M | $172.75M | $162.64M | $149.79M | $144.79M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $1.28B | $1.10B | $966.11M | $707.01M | $584.90M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $306.00K | $308.00K | $309.00K | $360.00K | $355.00K |
| Retained Earnings | $8.17M | $-221.65M | $-359.83M | $234.98M | $115.23M |
| Accumulated Other Comprehensive Income Loss | $-14.74M | $-10.07M | $-12.39M | $-4.85M | $-131.00K |
| Other Total Stockholders Equity | $831.82M | $790.36M | $758.30M | $722.43M | $690.33M |
| Total Stockholders Equity | $825.54M | $558.95M | $386.39M | $952.93M | $805.78M |
| Total Equity | $825.54M | $558.95M | $386.39M | $952.93M | $805.78M |
| Total Liabilities and Stockholders Equity | $2.10B | $1.66B | $1.35B | $1.66B | $1.39B |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $2.10B | $1.66B | $1.35B | $1.66B | $1.39B |
| Total Investments | $- | $- | $- | $- | $- |
| Total Debt | $126.23M | $142.12M | $188.87M | $130.97M | $115.14M |
| Net Debt | $-543.20M | $-103.33M | $160.60M | $-330.34M | $-162.62M |
Balance Sheet Charts
| Breakdown | March 31, 2025 | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $441.44M | $669.44M | $656.90M | $510.89M | $407.01M | $245.45M | $95.21M | $39.14M | $46.92M | $28.27M | $31.01M | $42.55M | $82.84M | $461.30M | $398.39M | $339.01M | $332.88M | $277.77M | $219.23M | $160.90M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $441.44M | $669.44M | $656.90M | $510.89M | $407.01M | $245.45M | $95.21M | $39.14M | $46.92M | $28.27M | $31.01M | $42.55M | $82.84M | $461.30M | $398.39M | $339.01M | $332.88M | $277.77M | $219.23M | $160.90M |
| Net Receivables | $298.22M | $296.44M | $311.47M | $301.11M | $279.17M | $298.40M | $292.77M | $275.06M | $257.75M | $253.40M | $249.09M | $225.69M | $224.76M | $186.43M | $186.38M | $161.49M | $160.00M | $160.96M | $134.09M | $127.29M |
| Inventory | $- | $- | $- | $- | $- | $1 | $1 | $- | $- | $- | $1 | $- | $1 | $- | $- | $- | $1 | $- | $1 | $- |
| Other Current Assets | $81.78M | $63.35M | $64.23M | $60.52M | $58.73M | $49.98M | $60.90M | $64.73M | $62.95M | $52.29M | $57.65M | $121.28M | $96.73M | $86.35M | $112.91M | $99.20M | $81.01M | $69.85M | $83.38M | $61.79M |
| Total Current Assets | $821.44M | $1.03B | $1.03B | $872.52M | $744.90M | $593.83M | $448.88M | $378.93M | $367.62M | $333.96M | $337.74M | $328.89M | $355.97M | $690.91M | $641.22M | $550.10M | $533.38M | $473.65M | $395.00M | $319.08M |
| Property Plant Equipment Net | $258.19M | $252.26M | $254.60M | $256.39M | $257.40M | $265.39M | $258.91M | $254.68M | $257.06M | $248.92M | $243.79M | $238.93M | $240.17M | $222.71M | $213.13M | $196.93M | $196.77M | $198.83M | $181.00M | $179.52M |
| Goodwill | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.40M | $662.46M | $662.43M |
| Intangible Assets | $34.13M | $34.37M | $34.73M | $35.09M | $35.45M | $35.81M | $36.36M | $36.91M | $37.46M | $38.01M | $38.85M | $39.68M | $40.52M | $41.36M | $42.64M | $43.92M | $45.20M | $46.47M | $48.42M | $50.37M |
| Goodwill and Intangible Assets | $696.53M | $696.76M | $697.12M | $697.48M | $697.84M | $698.21M | $698.75M | $699.30M | $699.85M | $700.40M | $701.24M | $702.08M | $702.92M | $703.76M | $705.03M | $706.31M | $707.59M | $708.87M | $710.88M | $712.80M |
| Long Term Investments | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $99.69M | $100.36M | $76.68M | $75.20M | $75.23M | $74.44M | $59.34M | $51.77M | $49.16M | $48.08M | $27.02M | $26.44M | $25.81M | $25.13M | $1.27M | $540.00K | $556.00K | $536.00K | $477.00K | $469.00K |
| Other Non-Current Assets | $21.52M | $22.25M | $23.05M | $18.45M | $20.41M | $24.97M | $20.83M | $22.26M | $22.03M | $21.13M | $18.63M | $19.12M | $19.48M | $17.42M | $16.48M | $15.83M | $13.06M | $8.79M | $8.77M | $10.26M |
| Total Non-Current Assets | $1.08B | $1.07B | $1.05B | $1.05B | $1.05B | $1.06B | $1.04B | $1.03B | $1.03B | $1.02B | $990.68M | $986.57M | $988.38M | $969.02M | $935.92M | $919.61M | $917.98M | $917.03M | $901.14M | $903.05M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $0 | $- | $- | $- |
| Total Assets | $1.90B | $2.10B | $2.08B | $1.92B | $1.80B | $1.66B | $1.49B | $1.41B | $1.40B | $1.35B | $1.33B | $1.32B | $1.34B | $1.66B | $1.58B | $1.47B | $1.45B | $1.39B | $1.30B | $1.22B |
| Account Payables | $10.72M | $32.53M | $26.20M | $27.39M | $24.40M | $31.87M | $29.02M | $33.61M | $37.11M | $33.07M | $28.25M | $28.80M | $25.43M | $25.68M | $25.05M | $23.33M | $21.35M | $26.55M | $15.88M | $14.88M |
| Short Term Debt | $- | $- | $- | $- | $- | $- | $20.28M | $74.99M | $115.00M | $69.27M | $158.39M | $268.47M | $18.46M | $- | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $670.94M | $638.42M | $616.70M | $559.86M | $518.75M | $490.56M | $466.04M | $462.73M | $417.93M | $401.37M | $367.22M | $344.64M | $303.85M | $282.22M | $277.81M | $255.66M | $202.61M | $195.35M |
| Other Current Liabilities | $- | $1.07B | $344.21M | $327.28M | $315.55M | $333.40M | $280.46M | $253.29M | $263.74M | $238.40M | $216.31M | $180.32M | $168.31M | $186.90M | $188.28M | $167.06M | $148.15M | $157.89M | $139.91M | $127.75M |
| Total Current Liabilities | $10.72M | $1.10B | $1.04B | $993.09M | $956.64M | $925.13M | $848.52M | $852.44M | $881.89M | $803.47M | $820.87M | $878.96M | $579.43M | $557.22M | $517.18M | $472.61M | $447.31M | $440.11M | $358.40M | $337.98M |
| Long Term Debt | $126.66M | $126.23M | $128.28M | $131.80M | $136.16M | $142.12M | $143.04M | $139.39M | $142.69M | $138.87M | $139.20M | $134.98M | $141.62M | $130.97M | $128.21M | $112.85M | $114.14M | $99.49M | $110.67M | $114.98M |
| Deferred Revenue Non-Current | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $1.07M | $- | $1.00M | $- | $1.08M | $- | $- | $- | $13.55M | $- | $- |
| Deferred Tax Liabilities Non-Current | $1.84M | $1.80M | $2.29M | $2.29M | $2.36M | $2.40M | $1.13M | $1.10M | $1.09M | $1.07M | $911.00K | $1.00M | $1.05M | $1.08M | $17.60M | $16.24M | $14.88M | $13.55M | $19.86M | $15.34M |
| Other Non-Current Liabilities | $52.95M | $42.73M | $30.70M | $29.27M | $29.08M | $30.62M | $23.12M | $22.95M | $22.79M | $22.70M | $17.56M | $17.26M | $17.22M | $17.75M | $16.06M | $16.13M | $16.11M | $443.00K | $15.59M | $15.76M |
| Total Non-Current Liabilities | $181.45M | $170.77M | $161.27M | $163.36M | $167.60M | $172.75M | $167.29M | $163.44M | $166.57M | $162.64M | $157.67M | $153.24M | $159.90M | $149.79M | $161.88M | $145.22M | $145.13M | $144.79M | $146.12M | $146.08M |
| Other Liabilities | $1.11B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $1.30B | $1.28B | $1.20B | $1.16B | $1.12B | $1.10B | $1.02B | $1.02B | $1.05B | $966.11M | $978.54M | $1.03B | $739.33M | $707.01M | $679.06M | $617.83M | $592.43M | $584.90M | $504.51M | $484.06M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $- | $306.00K | $311.00K | $310.00K | $310.00K | $308.00K | $307.00K | $306.00K | $306.00K | $309.00K | $309.00K | $309.00K | $336.00K | $360.00K | $359.00K | $358.00K | $359.00K | $355.00K | $357.00K | $354.00K |
| Retained Earnings | $- | $8.17M | $65.64M | $-30.79M | $-119.14M | $-221.65M | $-300.20M | $-371.02M | $-408.10M | $-359.83M | $-380.12M | $-446.14M | $-120.81M | $234.98M | $184.95M | $142.31M | $158.53M | $115.23M | $111.81M | $70.35M |
| Accumulated Other Comprehensive Income Loss | $-11.62M | $-14.74M | $-9.18M | $-12.59M | $-12.04M | $-10.07M | $-12.87M | $-11.19M | $-11.31M | $-12.39M | $-16.05M | $-9.97M | $-6.39M | $-4.85M | $-3.24M | $-1.76M | $-2.27M | $-131.00K | $-2.12M | $-3.22M |
| Other Total Stockholders Equity | $383.52M | $831.82M | $824.67M | $806.67M | $802.41M | $790.36M | $783.67M | $772.97M | $766.37M | $758.30M | $745.74M | $739.06M | $731.88M | $722.43M | $716.02M | $710.97M | $702.30M | $690.33M | $681.59M | $670.59M |
| Total Stockholders Equity | $371.90M | $825.54M | $881.44M | $763.60M | $671.54M | $558.95M | $470.91M | $391.06M | $347.26M | $386.39M | $349.88M | $283.25M | $605.02M | $952.93M | $898.09M | $851.88M | $858.93M | $805.78M | $791.63M | $738.07M |
| Total Equity | $371.90M | $825.54M | $881.44M | $763.60M | $671.54M | $558.95M | $470.91M | $391.06M | $347.26M | $386.39M | $349.88M | $283.25M | $605.02M | $952.93M | $898.09M | $851.88M | $858.93M | $805.78M | $791.63M | $738.07M |
| Total Liabilities and Stockholders Equity | $1.90B | $2.10B | $2.08B | $1.92B | $1.80B | $1.66B | $1.49B | $1.41B | $1.40B | $1.35B | $1.33B | $1.32B | $1.34B | $1.66B | $1.58B | $1.47B | $1.45B | $1.39B | $1.30B | $1.22B |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $1.90B | $2.10B | $2.08B | $1.92B | $1.80B | $1.66B | $1.49B | $1.41B | $1.40B | $1.35B | $1.33B | $1.32B | $1.34B | $1.66B | $1.58B | $1.47B | $1.45B | $1.39B | $1.30B | $1.22B |
| Total Investments | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $126.66M | $126.23M | $128.28M | $153.72M | $136.16M | $142.12M | $143.04M | $194.39M | $257.69M | $188.87M | $278.90M | $384.68M | $141.62M | $130.97M | $128.21M | $112.85M | $114.14M | $115.14M | $110.67M | $114.98M |
| Net Debt | $-314.78M | $-543.20M | $-528.62M | $-357.17M | $-270.85M | $-103.33M | $47.83M | $155.25M | $210.77M | $160.60M | $247.90M | $342.13M | $58.78M | $-330.34M | $-270.18M | $-226.16M | $-218.73M | $-162.62M | $-108.56M | $-45.92M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $404.39M | $282.81M | $245.37M | $181.85M | $145.38M |
| Depreciation and Amortization | $29.25M | $26.33M | $22.34M | $21.12M | $19.53M |
| Deferred Income Tax | $-26.63M | $-25.12M | $-23.01M | $-37.11M | $527.00K |
| Stock Based Compensation | $25.51M | $20.52M | $21.41M | $14.47M | $13.78M |
| Change in Working Capital | $157.18M | $106.49M | $106.06M | $66.71M | $66.26M |
| Accounts Receivables | $2.24M | $-48.28M | $-66.92M | $-24.98M | $-5.53M |
| Inventory | $- | $66.19M | $- | $24.98M | $5.53M |
| Accounts Payables | $-2.96M | $1.05M | $6.43M | $1.87M | $-2.60M |
| Other Working Capital | $157.90M | $87.52M | $166.54M | $64.84M | $68.85M |
| Other Non Cash Items | $19.11M | $22.35M | $15.89M | $16.30M | $13.20M |
| Net Cash Provided by Operating Activities | $608.82M | $433.37M | $388.05M | $263.33M | $258.68M |
| Investments in Property Plant and Equipment | $- | $-36.65M | $-36.88M | $-28.27M | $-31.34M |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $-28.31M | $2.02M | $-1.86M | $-3.09M | $126.00K |
| Net Cash Used for Investing Activities | $-28.31M | $-34.63M | $-38.74M | $-31.36M | $-31.21M |
| Debt Repayment | $- | $-50.00M | $50.00M | $- | $- |
| Common Stock Issued | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-169.87M | $-144.02M | $-847.85M | $-62.10M | $-98.27M |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $15.86M | $11.38M | $22.07M | $17.64M | $15.99M |
| Net Cash Used Provided by Financing Activities | $-154.01M | $-182.64M | $-775.77M | $-44.45M | $-82.28M |
| Effect of Forex Changes on Cash | $-2.51M | $1.08M | $-6.57M | $-3.97M | $666.00K |
| Net Change in Cash | $423.99M | $217.18M | $-433.04M | $183.54M | $145.85M |
| Cash at End of Period | $669.44M | $245.45M | $28.27M | $461.30M | $277.77M |
| Cash at Beginning of Period | $245.45M | $28.27M | $461.30M | $277.77M | $131.92M |
| Operating Cash Flow | $608.82M | $433.37M | $388.05M | $263.33M | $258.68M |
| Capital Expenditure | $- | $-36.65M | $-36.88M | $-28.27M | $-31.34M |
| Free Cash Flow | $608.82M | $396.73M | $351.17M | $235.06M | $227.34M |
Cash Flow Charts
| Breakdown | March 31, 2025 | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $114.59M | $117.02M | $96.43M | $88.35M | $102.59M | $78.30M | $70.55M | $61.07M | $72.89M | $68.67M | $66.03M | $49.36M | $61.31M | $50.03M | $48.57M | $39.93M | $43.31M | $50.87M | $41.46M | $24.10M |
| Depreciation and Amortization | $6.93M | $7.51M | $7.52M | $7.24M | $6.99M | $6.97M | $6.88M | $6.52M | $5.96M | $5.90M | $5.79M | $5.54M | $5.11M | $5.46M | $5.33M | $5.23M | $5.09M | $5.48M | $4.94M | $4.65M |
| Deferred Income Tax | $749.00K | $-24.20M | $-1.51M | $-54.00K | $-865.00K | $-13.81M | $-7.60M | $-2.65M | $-1.06M | $-20.89M | $-687.00K | $-726.00K | $-713.00K | $-40.41M | $632.00K | $1.38M | $1.29M | $-6.38M | $4.50M | $1.34M |
| Stock Based Compensation | $- | $5.89M | $11.73M | $3.59M | $4.31M | $5.17M | $5.01M | $4.91M | $5.44M | $5.59M | $5.79M | $5.65M | $4.37M | $3.98M | $4.05M | $3.57M | $2.87M | $2.96M | $2.76M | $2.62M |
| Change in Working Capital | $- | $78.81M | $29.01M | $11.19M | $38.18M | $72.82M | $32.91M | $7.21M | $-6.45M | $74.63M | $26.78M | $32.58M | $-27.94M | $47.12M | $9.87M | $8.81M | $903.00K | $48.73M | $2.42M | $8.56M |
| Accounts Receivables | $- | $15.27M | $-10.32M | $-21.83M | $19.12M | $-8.97M | $-17.58M | $-17.39M | $-4.34M | $-27.86M | $-23.38M | $-835.00K | $-38.22M | $-24.98M | $-24.69M | $-1.44M | $1.09M | $-5.53M | $-7.12M | $9.22M |
| Inventory | $- | $- | $- | $- | $- | $8.97M | $17.58M | $17.39M | $- | $- | $23.38M | $- | $- | $35.13M | $- | $- | $-19.27M | $-2.69M | $- | $- |
| Accounts Payables | $- | $64.00K | $-576.00K | $4.90M | $-7.35M | $1.97M | $-3.26M | $-2.12M | $4.46M | $5.66M | $-1.78M | $3.59M | $-1.04M | $-284.00K | $2.42M | $2.37M | $-2.64M | $3.01M | $1.56M | $-364.00K |
| Other Working Capital | $-27.54M | $63.47M | $39.90M | $28.12M | $62.70M | $70.85M | $36.17M | $9.33M | $-6.57M | $96.83M | $28.57M | $29.82M | $11.33M | $37.26M | $7.45M | $6.45M | $21.72M | $53.94M | $858.00K | $8.92M |
| Other Non Cash Items | $3.56M | $5.65M | $5.91M | $41.08M | $1.47M | $6.95M | $6.64M | $5.46M | $3.30M | $2.78M | $4.78M | $4.21M | $4.12M | $4.71M | $3.89M | $3.84M | $3.86M | $3.84M | $3.69M | $3.00M |
| Net Cash Provided by Operating Activities | $125.84M | $190.67M | $149.07M | $116.40M | $152.68M | $156.40M | $114.39M | $82.52M | $80.08M | $136.68M | $108.49M | $96.62M | $46.26M | $70.89M | $72.35M | $62.76M | $57.32M | $105.50M | $59.76M | $44.27M |
| Investments in Property Plant and Equipment | $- | $-7.64M | $-10.54M | $-12.87M | $-5.50M | $-9.99M | $-8.70M | $-8.45M | $-9.51M | $-9.24M | $-7.18M | $-11.20M | $-9.26M | $-9.12M | $-6.64M | $-6.01M | $-6.51M | $-7.79M | $-8.67M | $-9.32M |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $-9.99M | $81.00K | $51.00K | $81.00K | $8.03M | $1.99M | $41.00K | $-21.00K | $10.00K | $23.00K | $-8.00K | $73.00K | $-1.95M | $-28.27M | $40.00K | $11.00K | $-3.14M | $52.00K | $26.00K | $9.00K |
| Net Cash Used for Investing Activities | $-9.99M | $-7.56M | $-10.49M | $-12.79M | $2.53M | $-8.00M | $-8.66M | $-8.47M | $-9.50M | $-9.22M | $-7.19M | $-11.13M | $-11.21M | $-9.12M | $-6.60M | $-6.00M | $-9.65M | $-7.73M | $-8.64M | $-9.31M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $-55.00M | $-60.00M | $65.00M | $-89.70M | $-110.00M | $249.70M | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $-8.33M | $666.00K | $7.66M | $1.52M | $5.73M | $- | $- | $- | $892.00K | $- | $- | $2.43M | $- | $- | $9.10M | $- | $- | $- |
| Common Stock Repurchased | $-371.90M | $-169.87M | $- | $- | $- | $- | $- | $-23.87M | $-120.15M | $-47.18M | $- | $-374.72M | $-425.95M | $- | $-6.22M | $-55.88M | $- | $-47.45M | $- | $-9.05M |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $25.93M | $1.26M | $6.27M | $666.00K | $7.66M | $1.52M | $5.73M | $1.66M | $2.46M | $5.76M | $892.00K | $1.55M | $13.87M | $2.43M | $1.01M | $5.10M | $9.10M | $7.24M | $6.78M | $645.00K |
| Net Cash Used Provided by Financing Activities | $-345.97M | $-168.61M | $6.27M | $666.00K | $7.66M | $1.52M | $-49.27M | $-82.21M | $-52.68M | $-131.12M | $-109.11M | $-123.46M | $-412.08M | $2.43M | $-5.21M | $-50.78M | $9.10M | $-40.21M | $6.78M | $-8.41M |
| Effect of Forex Changes on Cash | $2.12M | $-1.96M | $1.14M | $-389.00K | $-1.31M | $321.00K | $-382.00K | $375.00K | $767.00K | $915.00K | $-3.74M | $-2.32M | $-1.43M | $-1.29M | $-1.17M | $147.00K | $-1.66M | $983.00K | $427.00K | $358.00K |
| Net Change in Cash | $-228.00M | $12.54M | $146.01M | $103.88M | $161.56M | $150.24M | $56.07M | $-7.78M | $18.66M | $-2.74M | $-11.54M | $-40.29M | $-378.46M | $62.92M | $59.38M | $6.13M | $55.11M | $58.54M | $58.32M | $26.90M |
| Cash at End of Period | $441.44M | $669.44M | $656.90M | $510.89M | $407.01M | $245.45M | $95.21M | $39.14M | $46.92M | $28.27M | $31.01M | $42.55M | $82.84M | $461.30M | $398.39M | $339.01M | $332.88M | $277.77M | $219.23M | $160.90M |
| Cash at Beginning of Period | $669.44M | $656.90M | $510.89M | $407.01M | $245.45M | $95.21M | $39.14M | $46.92M | $28.27M | $31.01M | $42.55M | $82.84M | $461.30M | $398.39M | $339.01M | $332.88M | $277.77M | $219.23M | $160.90M | $134.00M |
| Operating Cash Flow | $125.84M | $190.67M | $149.07M | $116.40M | $152.68M | $156.40M | $114.39M | $82.52M | $80.08M | $136.68M | $108.49M | $96.62M | $46.26M | $70.89M | $72.35M | $62.76M | $57.32M | $105.50M | $59.76M | $44.27M |
| Capital Expenditure | $- | $-7.64M | $-10.54M | $-12.87M | $-5.50M | $-9.99M | $-8.70M | $-8.45M | $-9.51M | $-9.24M | $-7.18M | $-11.20M | $-9.26M | $-9.12M | $-6.64M | $-6.01M | $-6.51M | $-7.79M | $-8.67M | $-9.32M |
| Free Cash Flow | $125.84M | $183.02M | $138.54M | $103.53M | $147.18M | $146.41M | $105.68M | $74.07M | $70.56M | $127.44M | $101.31M | $85.42M | $37.00M | $61.78M | $65.71M | $56.75M | $50.81M | $97.71M | $51.09M | $34.94M |
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
Healthcare
Medical - Diagnostics & Research
$306.35
Stock Price
$8.80B
Market Cap
5.90K
Employees
Cincinnati, OH
Location
Revenue (FY 2024)
$2.11B
11.8% YoY
Net Income (FY 2024)
$404.39M
43.0% YoY
EPS (FY 2024)
$12.63
42.2% YoY
Free Cash Flow (FY 2024)
$608.82M
53.5% YoY
Profitability
Gross Margin
31.1%
Net Margin
19.2%
ROE
49.0%
ROA
19.2%
Valuation
P/E Ratio
25.43
P/S Ratio
4.88
EV/EBITDA
21.80
Market Cap
$8.80B
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$608.82M
40.5% YoY
Free Cash Flow
$608.82M
53.5% YoY
Balance Sheet Summary
Total Assets
$2.10B
26.8% YoY
Total Debt
$126.23M
11.2% YoY
Shareholder Equity
$825.54M
46.6% YoY
Dividend Overview
No Dividend Data
Medpace Holdings, Inc. doesn't currently pay dividends.
Medpace Holdings Dividends
Explore Medpace Holdings's dividend history, including dividend yield, payout ratio, and historical payments.
Medpace Holdings News
Read the latest news about Medpace Holdings, including recent articles, headlines, and updates.
Medpace Holdings, Inc. (MEDP) Q1 2025 Earnings Call Transcript
Medpace Holdings, Inc. (NASDAQ:MEDP ) Q1 2025 Earnings Conference Call April 22, 2025 9:00 AM ET Company Participants Lauren Morris - Director, Investor Relations August Troendle - Chief Executive Officer Jesse Geiger - President Kevin Brady - Chief Financial Officer Conference Call Participants David Windley - Jefferies Max Smock - William Blair Ann Hynes - Mizuho Dan Leonard - UBS Eric Coldwell - Baird Charles Rhyee - TD Cowen Michael Cherny - Leerink Partners Jailendra Singh - Truist Securities Justin Bowers - Deutsche Bank Operator Good day, ladies and gentlemen, and welcome to the Medpace First Quarter 2025 Earnings Conference Call. At this time all participants are in a listen-only mode.
Medpace Holdings, Inc. Reports First Quarter 2025 Results
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Revenue for the three months ended March 31, 2025 increased 9.3% to $558.6 million, compared to $511.0 million for the comparable prior-year period. On a constant currency basis, revenue for the first quarter of 2025 increased 9.5% compared to the first quarter of 2024. Backlog as of March 31, 2025 decre.
1 Spectacular Growth Stock Down 34% to Buy Hand Over Fist
Not only are biotech stocks subject to the boom-or-bust nature of their therapeutics, but they also operate in a cyclical industry exposed to the broader market's whims. One less stressful way to take part in the booming industry is to invest in "picks-and-shovels" companies that support biotech stocks but aren't reliant upon any single clinical trial outcome to profit.
Medpace Holdings: It Might Be Time To Buy In
Medpace has historically shown incredible growth and strong return metrics. It is currently down 35% from its ATH. The valuation has come down to more favorable levels. Risks include uncertainties around pharmaceutical spending and backlogs, which could make the current valuation appear too high.
Medpace Holdings, Inc. to Report First Quarter 2025 Financial Results on April 21, 2025
CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2025 financial results after the market close on Monday, April 21, 2025. The Company will host a conference call the following morning, Tuesday, April 22, 2025, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 1.
An Investigation Has Been Launched Into Medpace Holdings, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / March 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Invites Shareholders With Losses In Medpace Holdings, Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Medpace Holdings, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for MEDP.